Q4 Fiscal 2023 Highlights Q4 2023 revenues grew 46.8% year-over-year to $6.1 million Q4 2023 revenues grew 1.7% from the previous quarter Gross profit of $1.8 million, increased 37.4% year-over-year Cash position… Read More
Until recently, the way the medical system categorized endometrial cancers was fraught with challenges. Patients were classified depending on how their tumours looked under a microscope — a system that… Read More
VANCOUVER, BC — Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, reports financial results… Read More
VANCOUVER, BC — Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, announced that it has commenced an underwritten public offering of $225.0 million of its common shares and, in… Read More
TORONTO, ON — Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that Health Canada has granted Market Authorization for the expanded use of PrKALYDECO® (ivacaftor) for the treatment of cystic fibrosis (CF) in children ages 2 months… Read More
